Literature DB >> 34763823

100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?

William H Herman1, Shihchen Kuo2.   

Abstract

The discovery of insulin 100 years ago and subsequent improvements in insulin formulations and delivery devices have changed the lives of people with diabetes. Unfortunately, the average price of insulin in the United States has nearly tripled over the past decade, and the high cost of insulin has become a barrier to diabetes treatment. On the 100th anniversary of insulin's discovery, this life-saving treatment is financially out of reach for as many as one-third of people with diabetes. The challenge now is to ensure that insulin is available for all people with diabetes who need it. We explore reasons for the high cost of insulin and recommend some clinical and policy interventions to improve insulin access and affordability.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Access; Affordability; Biosimilar medications; Cost; Insulin; Value-based pricing

Mesh:

Substances:

Year:  2021        PMID: 34763823      PMCID: PMC8597930          DOI: 10.1016/j.ecl.2021.09.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.748


  43 in total

1.  National trends in prescription drug expenditures and projections for 2019.

Authors:  Glen T Schumock; JoAnn Stubbings; James M Hoffman; Michelle D Wiest; Katie J Suda; Matthew H Rim; Mina Tadrous; Eric M Tichy; Sandra Cuellar; John S Clark; Linda M Matusiak; Robert J Hunkler; Lee C Vermeulen
Journal:  Am J Health Syst Pharm       Date:  2019-07-18       Impact factor: 2.637

2.  Insulins for type 2 diabetes.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2019-05-06       Impact factor: 1.909

Review 3.  Insulin Access and Affordability Working Group: Conclusions and Recommendations.

Authors:  William T Cefalu; Daniel E Dawes; Gina Gavlak; Dana Goldman; William H Herman; Karen Van Nuys; Alvin C Powers; Simeon I Taylor; Alan L Yatvin
Journal:  Diabetes Care       Date:  2018-05-08       Impact factor: 19.112

4.  Who Pays in Medicare Part D? Giving Plans More Skin in the Game.

Authors:  Erin E Trish; Paul B Ginsburg; Geoffrey F Joyce; Dana P Goldman
Journal:  N Engl J Med       Date:  2019-11-20       Impact factor: 91.245

5.  May your drug price be evergreen.

Authors:  Robin Feldman
Journal:  J Law Biosci       Date:  2018-12-07

Review 6.  Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.

Authors:  Dawn E DeWitt; Irl B Hirsch
Journal:  JAMA       Date:  2003-05-07       Impact factor: 56.272

7.  Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.

Authors:  Kasia J Lipska; Joseph S Ross; Holly K Van Houten; David Beran; John S Yudkin; Nilay D Shah
Journal:  JAMA       Date:  2014-06-11       Impact factor: 56.272

8.  Insulin prices, availability and affordability in 13 low-income and middle-income countries.

Authors:  Margaret Ewen; Huibert-Jan Joosse; David Beran; Richard Laing
Journal:  BMJ Glob Health       Date:  2019-06-11

Review 9.  A global perspective on the issue of access to insulin.

Authors:  David Beran; Maria Lazo-Porras; Camille M Mba; Jean Claude Mbanya
Journal:  Diabetologia       Date:  2021-01-23       Impact factor: 10.122

Review 10.  The Evolution of Insulin and How it Informs Therapy and Treatment Choices.

Authors:  Irl B Hirsch; Rattan Juneja; John M Beals; Caryl J Antalis; Eugene E Wright
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

View more
  1 in total

1.  Can nutrition interventions tackle the global insulin affordability via improving diabetes management and reducing insulin demand?

Authors:  Victoria Lu; Jiandi Zhang; Guoxun Chen
Journal:  Glob Health Res Policy       Date:  2022-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.